Beximco Pharmaceuticals PLC posted 13.1 percent year-on-year revenue growth in the first nine months of the just concluded fiscal year 2025-26, outpacing its peers, according to a BRAC EPL Stock Brokerage report released yesterday.

The company recorded Tk 4,142 crore in net revenue during the July-March period of the 2025-26 financial year, up from Tk 3,662 crore a year earlier

Shares of Beximco Pharmaceuticals gained 8 percent over the last two trading sessions on the Dhaka Stock Exchange (DSE), closing at Tk 145.3 today, following reports that the company may be delisted from the London Stock Exchange

Major indices of the stock market in Bangladesh fell yesterday, snapping a two-day gaining streak as investors cautiously traded select shares to pocket short-term gains amid price fluctuations resulting from earnings disclosures by listed companies..The DSEX, which reflects the cumulative

The Appellate Division of the Supreme Court yesterday stayed a part of the High Court order that instructed Bangladesh Bank to appoint a receiver to manage Beximco Pharmaceuticals Limited.

Production of active pharmaceutical ingredients (APIs) at the API Industrial Park in Gazaria of Munshiganj will begin next month, with ACME Laboratories set to commission its manufacturing unit despite the lack of gas supply.